Insider · CIK 0001652410
Beth Hecht
Files at XERS (Xeris Biopharma Holdings, Inc.). First filing Mar 21, 2025, latest Oct 2, 2026.
In brief
Beth Hecht files SEC Form 4 as officer at XERS (Xeris Biopharma Holdings, Inc.). Since Mar 21, 2025, Beth Hecht has reported 0 open-market buys worth $0 and 13 open-market sells worth $1.7M, the latest filed on Oct 2, 2026.
A track record needs three past buys with six months of prices behind them; Beth Hecht has 0, so none is measured yet.
The newest scored trade: sold $157k of XERS on Oct 1, 2026, filed Oct 2, 2026, scored 21 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 12 sells worth $1.5M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
XERS: Xeris Biopharma Holdings, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 21Weak | Xeris Biopharma Holdings, Inc. | $157k 16,666 shares | -1% | +75% from low-7% from high | |
| 21Weak | Xeris Biopharma Holdings, Inc. | $141k 16,666 shares | -1% | - | |
| 21Weak | Xeris Biopharma Holdings, Inc. | $134k 16,666 shares | -1% | +54% from low-18% from high | |
| 21Weak | Xeris Biopharma Holdings, Inc. | $134k 16,666 shares | -1% | +72% from low-19% from high | |
| 20Weak | Xeris Biopharma Holdings, Inc. | $101k 16,667 shares | -1% | +40% from low-39% from high | |
| 5Weak | Xeris Biopharma Holdings, Inc. | $104k 16,667 shares | -1% | +46% from low-37% from high | |
| 13Weak | Xeris Biopharma Holdings, Inc. | $100k 16,667 shares | -1% | +53% from low-39% from high | |
| 5Weak | Xeris Biopharma Holdings, Inc. | $104k 16,667 shares | -1% | +63% from low-39% from high | |
| 5Weak | Xeris Biopharma Holdings, Inc. | $124k 16,667 shares | -1% | +107% from low-26% from high | |
| 20Weak | Xeris Biopharma Holdings, Inc. | $124k 16,667 shares | -1% | +130% from low-26% from high | |
| 13Weak | Xeris Biopharma Holdings, Inc. | $117k 16,667 shares | -1% | +118% from low-30% from high | |
| 13Weak | Xeris Biopharma Holdings, Inc. | $123k 16,667 shares | -1% | +157% from low-25% from high | |
| 27Weak | XERSsell Xeris Biopharma Holdings, Inc. | $217k 40,000 shares | -3% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Oct 1, 2026 | XERS XERIS BIOPHARMA HOLDINGS, INC. | 16,666 0.01% of outstanding | $159k | Oct 1, 2026 | $275k |
| Jul 1, 2026 | XERS XERIS BIOPHARMA HOLDINGS, INC. | 49,998 0.03% of outstanding | $396k | Jul 1, 2026 | $205k |
| Mar 2, 2026 | XERS XERIS BIOPHARMA HOLDINGS, INC. | 66,668 0.04% of outstanding | $408k | Mar 2, 2026 | $248k |
| Nov 12, 2025 | XERS XERIS BIOPHARMA HOLDINGS, INC. | 66,668 0.04% of outstanding | $515k | Nov 11, 2025 | none |
| Mar 20, 2025 | XERS Xeris Biopharma Holdings, Inc. | 40,000 0.03% of outstanding | $206k | Mar 20, 2025 | none |
Transactions
Every row this insider has filed, 25 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -16,666 | $9.41 | $157k | 1,111,130 | 12 d ago |
| Sep 1, 2026 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -16,666 | $8.49 | $141k | 1,127,796 | 43 d ago |
| Aug 3, 2026 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -16,666 | $8.01 | $134k | 1,144,462 | Aug 4, 2026 |
| Jul 1, 2026 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -16,666 | $8.03 | $134k | 1,161,128 | Jul 2, 2026 |
| Jun 1, 2026 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -16,667 | $6.06 | $101k | 1,176,506 | Jun 2, 2026 |
| May 1, 2026 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -16,667 | $6.23 | $104k | 1,193,173 | May 1, 2026 |
| Apr 1, 2026 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -16,667 | $5.99 | $100k | 1,209,840 | Apr 3, 2026 |
| Mar 2, 2026 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -16,567 | $6.24 | $103k | 1,226,607 | Mar 4, 2026 |
| Mar 2, 2026 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -100 | $7.06 | $706 | 1,226,507 | Mar 4, 2026 |
| Jan 30, 2026 | XERS Xeris Biopharma Holdings, Inc. | AGrant or award Common Stock | +121,293 | $0.00 | $0 | 1,429,396 | Feb 2, 2026 |
| Jan 31, 2026 | XERS Xeris Biopharma Holdings, Inc. | FTax withholding Common Stock | -98,375 | $7.36 | $724k | 1,331,021 | Feb 2, 2026 |
| Jan 31, 2026 | XERS Xeris Biopharma Holdings, Inc. | FTax withholding Common Stock | -46,914 | $7.36 | $345k | 1,284,107 | Feb 2, 2026 |
| Jan 31, 2026 | XERS Xeris Biopharma Holdings, Inc. | FTax withholding Common Stock | -24,266 | $7.36 | $179k | 1,259,841 | Feb 2, 2026 |
| Feb 2, 2026 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -16,667 | $7.45 | $124k | 1,243,174 | Feb 2, 2026 |
| Jan 30, 2026 | XERS Xeris Biopharma Holdings, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +162,162 | $0.00 | $0 | 162,162 | Feb 2, 2026 |
| Jan 2, 2026 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -16,667 | $7.43 | $124k | 1,308,103 | Jan 5, 2026 |
| Dec 1, 2025 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -16,667 | $7.01 | $117k | 1,320,176 | Dec 2, 2025 |
| Nov 11, 2025 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -16,667 | $7.40 | $123k | 1,336,843 | Nov 13, 2025 |
| Mar 20, 2025 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock | -40,000 | $5.43 | $217k | 1,353,510 | Mar 21, 2025 |
| Jan 31, 2025 | XERS Xeris Biopharma Holdings, Inc. | FTax withholding Common Stock | -45,909 | $3.56 | $163k | 1,306,885 | Feb 3, 2025 |
| Jan 31, 2025 | XERS Xeris Biopharma Holdings, Inc. | FTax withholding Common Stock | -98,375 | $3.56 | $350k | 1,208,510 | Feb 3, 2025 |
| Jan 31, 2025 | XERS Xeris Biopharma Holdings, Inc. | AGrant or award Common Stock | +185,000 | $0.00 | $0 | 1,393,510 | Feb 3, 2025 |
| Jan 31, 2025 | XERS Xeris Biopharma Holdings, Inc. | AGrant or award Stock Appreciation Rightderivative | +300,000 | $0.00 | $0 | 300,000 | Feb 3, 2025 |
| Jan 3, 2025 | XERS Xeris Biopharma Holdings, Inc. | FTax withholding Common Stock | -32,039 | $3.61 | $116k | 1,352,794 | Jan 7, 2025 |
| Jan 31, 2024 | XERS Xeris Biopharma Holdings, Inc. | AGrant or award Common Stock | +750,000 | $0.00 | $0 | 1,554,968 | Jan 31, 2024 |
Questions about Beth Hecht
Answered from the filings on this page, as of the latest one.
Is Beth Hecht buying or selling?
In the last 12 months Beth Hecht reported 0 open-market buys worth $0 and 12 open-market sells worth $1.5M on SEC Form 4; the latest was sold $157k of XERS on Oct 1, 2026. Grants, option exercises and tax withholding are not counted.
How did Beth Hecht's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Beth Hecht has 0.
Where does Beth Hecht file Form 4?
Beth Hecht has filed Form 4 at XERS (Xeris Biopharma Holdings, Inc.) as See Remarks. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.